BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the third quarter ended September 30, 2025. “During the third quarter, we delivered on our revenue expectations despite challenging market conditions,” said Masoud Toloue, Chief Exe...
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, November 10, 2025, at 4:30 p.m. E.T., to discuss its third quarter 2025 financial results. Quanterix will issue a press release regarding its third quarter 2025 financial results...
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by...
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its executive leadership team will present at the Canaccord Genuity 45th Annual Growth Conference in Boston, Massachusetts on Tuesday, August 12th, at 3:30 p.m. ET. Quanterix will also host one-on-one meetings with insti...
Quanterix Corporation (NASDAQ:QTRX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 AM ET Company Participants Joshua Young - Corporate Participant Masoud Toloue - President, CEO & Director Vandana Sriram - CFO & Treasurer Conference Call Participants Michael Aaron Cherny - Leerink Partners LLC, Research Division Thomas DeBourcy - Nephron Research Operator Good day, everyone, and thank yo...
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. “Through our combination with Akoya Biosciences, we have created a high-margin, high-throughput business with a compelling opportunity to deliver profitable growt...
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 7, 2025, at 4:30 p.m. E.T., to discuss its second quarter 2025 financial results. Quanterix will issue a press release regarding its second quarter 2025 financial result...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.